Tyme Technologies Inc. appointed Michele Korfin as its chief commercial officer.
Korfin, who has over 20 years of experience in commercial sales and marketing in the oncology sector, was most recently at Kite Pharma Inc. where she oversaw market access strategy, including payer relations and reimbursement, for Yescarta, the first CAR-T cell therapy approved by the U.S. Food and Drug Administration to treat lymphoma.
Kite was acquired by Gilead Sciences Inc. for $11.9 billion in cash last year.
Korfin has also worked at Celgene Corp., where she spent a decade in various roles, including as head of the company's oncology sales force of over 120 representatives responsible for $650 million in revenue for pancreatic cancer treatment Abraxane.
Tyme Technologies is developing treatments for multiple cancer types.